内容

目次

<ol> Part 1: Introduction How Oncology Drug DevelopmentDiffers from Other Fields, 3 Ann T. Farrell, John Leighton, Grant Williams,and Richard Pazdur Part 2: Drug Discovery Natural Products, 13 RiyazN.H. Shah and Stanley B. Kaye History of the National Cancer InstituteDrug Discovery Program, 25 Edward A. Sausville and Jill I. JohnsonCombinatorial Chemistry in Anticancer Drug Development, 43 Ian R.Hardcastle and Roger J. Griffin Protein Crystallography in Drug Discovery,57 Martin Noble and Jane Endicott High-Throughput Screening, 69 RameshPadmanabha and Martyn Banks Bioinformatics and Data Mining in Support ofDrug Discovery, 79 Jeffrey Augen Genomics and Drug Development, 97Robert H. tePoele and Paul Workman The Application of Proteomics to DrugDevelopment, 117 Lasantha R. Bandara and Sandy Kennedy Part 3:Preclinical Models The Role of In Vitro Cell Line, Human Xenograft, andMouse Allograft Models in Cancer Drug Development, 129 TheodoraVoskoglou-Nomikos, Stefan D. Baral, and Lesley K. Seymour Drug-DrugInteraction Studies During Early Clinical Drug Development, 149 JochenKuhlmann and Christoph Wandel Gene-Targeted Mice in Anticancer DrugDevelopment, 163 Thomas M. Donnelly Part 4: Analytical LaboratoryTechniques Modern and Practical Guide for Bioanalysis, 187 Surendra K.Bansal and Zhenmin Liang Good Laboratory Practice and the Development ofAnticancer Agents, 195 Jinee D. Rizzo Part 5: Delivery SystemsPharmaceutical Formulation of Novel Anticancer Agents, 205 Bastiaan NuijenLiposomal Drug Carriers for Cancer Diagnosis and Therapy, 225 MartinBrandl Polymer-Drug Conjugates, 239 Ruth Duncan Prodrug DrugDevelopment and Retrometabolic Engineering, 261 Daniel R. BudmanPharmacokinetics and Pharmacodynamics in Anticancer Drug Development, 269Chris H. Takimoto Part 6: Clinical Studies Allometric Scaling:Predicting Pharmacokinetic Parameters of Drugs in Humans from Animals, 285Iftekhar Mahmood Phase I Clinical Trial Design, 297 Lawrence V.Rubinstein and Richard M. Simon Phase I Trial Design: Considerations inthe Pediatric Population, 309 Elizabeth Fox and Peter C. AdamsonMeasurements of Endpoints in Phase I Drug Design: Toxicity versusAlternatives, 319 Jerry M. Collins and Merrill J. Egorin Tumor ResponseEvaluation in Clinical Trials: RECIST, 331 A. Dimitrios ColevasPharmacogenetics and Cancer Chemotherapy, 343 Hany Ezzeldin and Robert B.Diasio Designs for Phase II and Phase III Cancer Drug Studies, 379 GaryL. Rosner and Donald A. Berry Part 7: Specific Issues in Drug DevelopmentData Verification and Scientific Auditing, 395 Raymond B. Weiss Roleof the Cooperative Groups in Drug Development, 403 Christopher W. Ryan andRichard L. Schilsky Drug Development in the Elderly, 411 Stuart M.Lichtman